#89: spikeoe: new investor
can anyone give an opion on this stock long term |
June 19, 2007
07:13:11 PM |
#88: NewsBot: ELN News Elan Announces Webcast of Fourth Quarter and Full Year 2006 Financial Results
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc announced today that it... |
January 22, 2007
09:00:00 AM |
#87: NewsBot: ELN News Elan to Present at the 25th Annual JP Morgan Healthcare Conference
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc announces that it will... |
December 20, 2006
05:30:00 AM |
#86: NewsBot: ELN News Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:... |
December 15, 2006
06:10:00 AM |
#85: NewsBot: ELN News Elan Announces Conversion and Redemption of 6.50% Convertible Guaranteed Notes Due 2008 and Redemption of 7.25% Guaranteed Senior Notes Due 2008
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (“Elan”) ... |
December 14, 2006
01:15:00 PM |
#84: NewsBot: ELN News Elan Announces Completion of Offering of US$615 Million Aggregate Principal Amount of Senior Notes
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (“Elan”) ... |
November 22, 2006
10:15:00 AM |
#83: NewsBot: ELN News Elan Announces Pricing of US$615 Million Aggregate Principal Amount of Senior Notes
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (“Elan”) ... |
November 17, 2006
01:49:00 PM |
#82: NewsBot: ELN News Elan Announces Proposed Offering of Senior Notes
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (“Elan”) ... |
November 8, 2006
11:30:00 PM |
#81: NewsBot: ELN News Elan to Present at the Cowen and Company 7th Annual Global Health Care Conference
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc announces today that its... |
November 1, 2006
06:01:00 AM |
#80: NewsBot: ELN News Elan Reports Third Quarter 2006 Financial Results
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) today announced... |
October 24, 2006
11:30:00 PM |
#79: NewsBot: ELN News TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week
DUBLIN, Ireland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elan Corporation, plc... |
October 24, 2006
05:00:00 AM |
#78: NewsBot: ELN News Elan Announces Webcast of Third Quarter 2006 Financial Results
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc announced today that it... |
October 9, 2006
01:15:00 PM |
#77: NewsBot: ELN News New Pharmacoeconomic Data on TYSABRI(R) Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis
CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB)... |
October 6, 2006
06:00:00 AM |
#76: NewsBot: ELN News Health Canada Grants Approval of TYSABRI(TM) (natalizumab) for the Treatment of Multiple Sclerosis Following Priority Review
MISSISSAUGA, Ontario & DUBLIN, Ireland--(BUSINESS WIRE)--Biogen Idec Canada and... |
October 4, 2006
05:00:00 AM |
#75: NewsBot: ELN News New Data Presented at ECTRIMS Congress Show TYSABRI(R) Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years
ZUG, Switzerland and DUBLIN, Ireland--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB)... |
September 29, 2006
06:00:00 AM |
| 
| 
| 
| 
| 
| 
